Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

A 3-Year Follow-up Comparison of Clinical Outcomes from Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)

Paola Ghione, Maria Lia Palomba, Markqayne D. Ray, Eve H. Limbrick-Oldfield, Jess Owen, Steve Kanters, Sabela Bobillo, Maria Teresa Ribeiro, Caron A. Jacobson, Sattva S. Neelapu, Herve Ghesquieres, Myrna Nahas, Sara Beygi, Anik R. Patel, John G. Gribben

Blood (2022) 140 (Supplement 1): 4676–4677.

https://doi.org/10.1182/blood-2022-170469

Published: 2022

Journal Articles

ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma

Olalekan O. Oluwole, Saad S. Kenderian, Parveen Shiraz, Reem Karmali, Ran Reshef, Philip L. McCarthy, Nilanjan Ghosh, Aleksandr Lazaryan, Simone Filosto, Soumya Poddar, Daqin Mao, Andrew Peng, Adrian Kilcoyne, Myrna Nahas, Sattva S. Neelapu

Blood (2022) 140 (Supplement 1): 10318–10320.

https://doi.org/10.1182/blood-2022-167688

Published: 2022

Journal Articles

Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma

Paola Ghione, M. Lia Palomba, Anik R. Patel, Sabela Bobillo, Kevin Deighton, Caron A. Jacobson, Myrna Nahas, Anthony J. Hatswell, A. Scott Jung, Steve Kanters, Julia Thornton Snider, Sattva S. Neelapu, Maria Teresa Ribeiro, M. Alan Brookhart, Herve Ghesquieres, John Radford, John G. Gribben

Blood (2022) 140 (8): 851–860.

https://doi.org/10.1182/blood.2021014375

Published: 2022

Includes: Supplemental data

Journal Articles

Treatment with DC/AML Fusion Vaccine and CD3xCD123 Bi-Specific T-Cell Engager (CD123-CODV-TCE) for Treatment of Acute Myeloid Leukemia

Dina Stroopinsky, Anita G. Koshy, Jessica J. Liegel, Myrna Nahas, Giulia Cheloni, Joshua Hauser, Daniela Torres, Poorva Bindal, Maryam Rahimian, Lina Bisharat, Paula Fraenkel, Ozlem Yildirim, Helene Bonnevaux, Stephane Guerif, Donald Kufe, Jacalyn Rosenblatt, David Avigan

Blood (2021) 138 (Supplement 1): 904.

https://doi.org/10.1182/blood-2021-148219

Published: 2021

Journal Articles

Prediction of Early Onset Cytokine Release Syndrome and Neurologic Events after Axicabtagene Ciloleucel in Large B-Cell Lymphoma Based on Machine Learning Algorithms

Qinghua Song, Tao Hu, Sattva S. Neelapu, Frederick L. Locke, Caron Jacobson, David B. Miklos, Olalekan O. Oluwole, Marie José Kersten, Max Topp, Jenny J. Kim, Kanwarjit Singh, Jorge Andrade, Lei Huang, Allen Xue, Marco Schupp, Myrna Nahas, Rhine R. Shen, Adrian Bot

Blood (2021) 138 (Supplement 1): 2833.

https://doi.org/10.1182/blood-2021-148580

Published: 2021

Journal Articles

A Comparison of Clinical Outcomes from Updated Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)

M. Lia Palomba, Paola Ghione, Anik R. Patel, Kevin Deighton, Caron Jacobson, Myrna Nahas, A Scott Jung, Anthony J Hatswell, Steve Kanters, Eve Limbrick-Oldfield, Sally W Wade, Julia Thornton Snider, Sattva S. Neelapu, Maria Teresa Riberio, John Gribben, John Radford, Sabela Bobillo, Herve Ghesquieres

Blood (2021) 138 (Supplement 1): 3543.

https://doi.org/10.1182/blood-2021-147608

Published: 2021

Journal Articles

ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL)

Saad S. Kenderian, MB, ChB, Olalekan O. Oluwole, MBBS, MPH, Philip L. McCarthy, MD, Ran Reshef, MD, Parveen Shiraz, MD, Omar Ahmed, PharmD, John Le Gall, MD MBA, Myrna Nahas, MD, Lily Tang, PhD, Sattva S. Neelapu, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-135988

Published: 2020

Journal Articles

Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naïve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study

Blood (2019) 134 (Supplement_1): 2015.

https://doi.org/10.1182/blood-2019-126238

Published: 2019

Journal Articles

Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma

Shira Orr, PhD, Marzia Capelletti, PhD MBBS, Haider Ghiasuddin, Dina Stroopinsky, PhD, Jessica Liegel, MD, Myrna Nahas, MD, Matthew Weinstock, MD, Adam Morin, Robin M. Joyce, MD, Salvia Jain, MD, Jon E. Arnason, MD, Maryam Rahimian, MD, Lina Bisharat, Shufen Meng, MD, Donald Kufe, MD, Jacalyn Rosenblatt, MD, David E. Avigan, MD

Blood (2019) 134 (Supplement_1): 392.

https://doi.org/10.1182/blood-2019-124768

Published: 2019

Journal Articles

Transcriptome Sequencing Demonstrates Unique Signature Associated with Durable Clinical Response to DC/AML Fusion Vaccine

Blood (2019) 134 (Supplement_1): 3832.

https://doi.org/10.1182/blood-2019-129451

Published: 2019

Journal Articles

T Cells Educated By DC/AML Fusions in the Context of 4-1BB Costimulation As a Potent Strategy for Adoptive Cellular Therapy

Jessica Liegel, MD, Dina Stroopinsky, PhD, Haider Ghiasuddin, Adam Morin, Marzia Capelletti, PhD MMSc, Shira Orr, PhD, Maryam Rahimian, MD, Lina Bisharat, Shufen Meng, MD, Myrna Nahas, MD, Matthew Weinstock, MD, Donald Kufe, MD, Jacalyn Rosenblatt, MD, David E. Avigan, MD

Blood (2019) 134 (Supplement_1): 2673.

https://doi.org/10.1182/blood-2019-131491

Published: 2019

Journal Articles

CD155-Tigit Pathway Modulation in Dendritic Cell/Acute Myeloid Leukemia Fusion Vaccine Model

Myrna Nahas, MD, Dina Stroopinsky, PhD, Marzia Capelletti, PhD MBBS, Jacalyn Rosenblatt, MD, Shira Orr, PhD, Haider Ghiasuddin, Adam Morin, Jessica Liegel, MD, Donald Kufe, MD, David E. Avigan, MD

Blood (2019) 134 (Supplement_1): 1386.

https://doi.org/10.1182/blood-2019-122438

Published: 2019

Journal Articles

Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies

Marzia Capelletti, PhD MMSc, Jessica Liegel, MD, Maria Themeli, MD PhD, Tuna Mutis, Dina Stroopinsky, PhD, Shira Orr, PhD, Daniela Torres, Adam Morin, Gertrude Gunset, BA, Haider Ghiasuddin, Maryam Rahimian, MD, Myrna Nahas, MD, Lina Bisharat, Shufen Meng, MD, Nikhil C. Munshi, MD, Donald Kufe, MD, Jacalyn Rosenblatt, MD, Michel Sadelain, MD PhD, David E. Avigan, MD

Blood (2019) 134 (Supplement_1): 3227.

https://doi.org/10.1182/blood-2019-124944

Published: 2019

Journal Articles

Ex-Vivo Stimulation with DC/AML Fusion Vaccine in the Presence of Cytokines Leads to an Activated T Cell Memory Phenotype and Enhanced Cytotoxicity with Potential for Use As an Adoptive Cellular Therapy

Jessica Liegel, MD, Dina Stroopinsky, PhD, Lourdes M. Mendez, MD PhD, Malgorzata McMasters, MD, Haider Ghiasuddin, BA, Maryam Rahimian, MD, Myrna Nahas, MD, Matthew Weinstock, MD, Salvia Jain, MD, Marzia Capelletti, PhD MMSc, Lina Bisharat, MA, Adam Morin, BA, Shira Orr, PhD, Jacalyn Rosenblatt, MD, Donald Kufe, MD, David E. Avigan, MD

Blood (2018) 132 (Supplement 1): 2728.

https://doi.org/10.1182/blood-2018-99-119996

Published: 2018

Journal Articles

A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model

Dina Stroopinsky, PhD, Jessica Liegel, MD, Kathleen M. Mahoney, MD PhD, Jacalyn Rosenblatt, MD, Benjamin L. Ebert, MD PhD, Richard M. Stone, MD, Maryam Rahimian, MD, Myrna Nahas, MD, Shira Orr, PhD, Marzia Capelletti, PhD MMSc, Matthew Weinstock, MD, Salvia Jain, MD, Lina Bisharat, MA, Haider Ghiasuddin, BA, Adam Morin, BA, Donald Kufe, MD, Gordon J Freeman, PhD, David E. Avigan, MD

Blood (2018) 132 (Supplement 1): 1446.

https://doi.org/10.1182/blood-2018-99-120259

Published: 2018

Journal Articles

Phase I/Ib Trial of the MUC1 Inhibitor GO-203-2C Alone and in Combination with Decitabine for Acute Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 2659.

https://doi.org/10.1182/blood.V130.Suppl_1.2659.2659

Published: 2017

Journal Articles

MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia

Blood (2017) 129 (13): 1791–1801.

https://doi.org/10.1182/blood-2016-07-730614

Published: 2017

Includes: Supplemental data

NARROW

A 3-Year Follow-up Comparison of Clinical Outcomes from Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)

ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma

Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma

Treatment with DC/AML Fusion Vaccine and CD3xCD123 Bi-Specific T-Cell Engager (CD123-CODV-TCE) for Treatment of Acute Myeloid Leukemia

Prediction of Early Onset Cytokine Release Syndrome and Neurologic Events after Axicabtagene Ciloleucel in Large B-Cell Lymphoma Based on Machine Learning Algorithms

A Comparison of Clinical Outcomes from Updated Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)

ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL)

Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naïve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study

Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma

Transcriptome Sequencing Demonstrates Unique Signature Associated with Durable Clinical Response to DC/AML Fusion Vaccine

T Cells Educated By DC/AML Fusions in the Context of 4-1BB Costimulation As a Potent Strategy for Adoptive Cellular Therapy

CD155-Tigit Pathway Modulation in Dendritic Cell/Acute Myeloid Leukemia Fusion Vaccine Model

Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies

Ex-Vivo Stimulation with DC/AML Fusion Vaccine in the Presence of Cytokines Leads to an Activated T Cell Memory Phenotype and Enhanced Cytotoxicity with Potential for Use As an Adoptive Cellular Therapy

A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model

Phase I/Ib Trial of the MUC1 Inhibitor GO-203-2C Alone and in Combination with Decitabine for Acute Myeloid Leukemia

MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only